Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

As the No.1 University in the world for sport-related subjects, we offer unrivalled research, teaching and partnerships across sport, exercise and health sciences. Our expertise spans the fields of ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...

Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Gilead Q3 profits soar, boosting full-year earnings forecast with strong HIV & COVID-19 treatment sales. Discover their impressive growth story.

Academic programs include pharmaceutical sciences, audiology and an accelerated nursing track. Sagendorf said the university acquired the property — which sits along Locust Grove south of the ...

Explore the breadth of our life sciences degrees, spanning the full breadth of life sciences from molecules through to ecosystems. Learn more about the expertise of our research labs where we deliver ...